Robotic Telesurgery in Urology
Part of paid clinical trials in Cleveland, Ohio.
- Sponsor
- Case Comprehensive Cancer Center
- Study ID
- NCT07541066
- Status
- Withdrawn
Conditions
Eligibility Criteria
- Sex
- MALE
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- High-Intensity Focused Ultrasound (HIFU) robotic device — PROCEDUREParticipants will receive surgery using the High-Intensity Focused Ultrasound (HIFU) robotic device, using the existing, secured network as part of the Cleveland Clinic infrastructure, to deliver focal ablative treatment for prostate cancer.
Study Details
The goal of this clinical trial is to confirm the safety and feasibility of robotic telesurgery when used for the surgical management of prostate cancer in participates undergoing treatment for prostate cancer. In this clinical trial, participants will receive robotic telesurgery treatment for prostate cancer.
Key Dates
- Start date
- May 31, 2026
- Status verified
- Apr 2026
- Primary completion
- Sep 30, 2026
- Completion
- Mar 31, 2027
Study Design
- Enrollment
- 0 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Robotic telesurgery
Primary Outcome Measure
Surgical success rate [ Time Frame: Day 1 (up to 90 days) ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Case Comprehensive Cancer Center, Cleveland Clinic Foundation Glickman Urological Institute | Cleveland | Ohio | 44195 | - |
Find similar trials in Cleveland, OH
By condition
By specialty
Related Studies
- Integrated Cancer Repository for Cancer ResearchRecruiting · University of Nebraska · Greenwood Village, Colorado
- A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical StudyPHASE2 · Recruiting · Astellas Pharma Global Development, Inc. · Anchorage, Alaska
- International Registry for Men With Advanced Prostate Cancer (IRONMAN)Recruiting · Prostate Cancer Clinical Trials Consortium · Birmingham, Alabama
- Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate CancerPHASE1 · Recruiting · Amgen · Duarte, California